Yesterday, the FDA’s Arthritis Advisory Committee convened for a vote on whether to recommend approval of Eli Lilly’s baricitinib, a Janus kinase (JAK) inhibitor that the company hopes to sell as Olumiant for the treatment of rheumatoid arthritis (RA). The advisory committee voted in favor of recommending approval of a dose of 2 mg and against recommending approval of a higher 4-mg dose because of concerns about safety, including the risk of thrombosis.
Yesterday, the FDA’s Arthritis Advisory Committee convened for a vote on whether to recommend approval of Eli Lilly’s baricitinib, a Janus kinase (JAK) inhibitor that the company hopes to sell as Olumiant for the treatment of rheumatoid arthritis (RA). The advisory committee voted in favor of recommending approval of a dose of 2 mg and against recommending approval of a higher 4-mg dose because of concerns about safety, including the risk of thrombosis.
While the FDA’s briefing document for the committee meeting said that the agency’s review team agreed that Eli Lilly’s data demonstrated the efficacy of the proposed drug at both doses, it had lingering concerns about safety and noted that many adverse events (AEs) associated with baricitinib appeared to be dose-dependent. Because Eli Lilly’s trial design for baricitinib, limited safety data for the 2-mg dose complicated the benefit/risk assessment of the lower dose.
"While we are disappointed with the Advisory Committee's assessment of the data for the 4-mg dose, we are confident in the positive benefit—risk profile of both the 2-mg and the 4-mg doses. We look forward to continuing our work with the FDA on our New Drug Application and are hopeful that baricitinib will receive approval in the coming months,” Christi Shaw, MBA, president of Lilly Bio-Medicines, said in a statement.
Baricitinib had been widely believed to have blockbuster potential in the RA space, given the fact that it outperformed adalimumab (Humira) in terms of patient-reported outcomes in a phase 3 study, and has an oral route of administration (while anti—tumor necrosis factor biologics and biosimilars must be infused or injected). With biosimilars for the top-selling Humira not expected to launch in the United States until 2023, baricitinib could, if approved, exert pressure on Humira.
While the advisory committee’s assessment came as a disappointment for Eli Lilly, this week’s vote is not the first such setback for baricitinib; the FDA issued a Complete Response Letter for baricitinib in April 2017 after concerns about safety. In fact, JAK inhibitors as a class have come under scrutiny for their safety profiles; a recent systematic review of the FDA’s Adverse Event Reporting System found elevated reporting for thromboembolic AEs for 2 approved JAK inhibitors, tofacitinib (Xeljanz) and ruxolitinib (Jakafi), raising the question of whether a class-wide safety issue might exist for JAK inhibitors.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Eye on Pharma: EU Biosimilar Approval, Launches and Product Returns, Denosumab Switching Data
July 10th 2024The European Union approves a tocilizumab biosimilar and the US sees another launch, Genentech’s ophthalmology biobetter returns to the market, and Samsung Bioepis shares data on switching to its denosumab biosimilar.